Quick Answer
Inhibitor Therapeutics, Inc. reported Research And Development Expense of $1.70 million for the year ending 2025.
- Inhibitor Therapeutics, Inc. showed a decrease of -3.5% in Research And Development Expense from 2024 to 2025.
- This data is from Inhibitor Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: $1.05 million | Q1 2014: $25.3 thousand | Q2 2014: $1.93 million | Q3 2014: $167.0 thousand | Q1 2015: $313.0 thousand | Q2 2015: $300.3 thousand | Q3 2015: $601.7 thousand | Q1 2016: $582.5 thousand | Q2 2016: $605.5 thousand | Q3 2016: $720.3 thousand | Q1 2017: $818.3 thousand | Q2 2017: $440.8 thousand | Q3 2017: $433.5 thousand | Q1 2018: $674.0 thousand | Q2 2018: $528.9 thousand | Q3 2018: $775.4 thousand | Q1 2019: $196.8 thousand | Q2 2019: $303.6 thousand | Q3 2019: $364.4 thousand | Q1 2020: $97.5 thousand | Q2 2020: $52.7 thousand | Q3 2020: $32.5 thousand | Q1 2021: $3.9 thousand | Q2 2021: $950.00 | Q3 2021: $0.00 | Q1 2022: $0.00 | Q2 2022: $6.2 thousand | Q3 2022: $0.00 | Q1 2023: $201.4 thousand | Q2 2023: $234.0 thousand | Q3 2023: $260.8 thousand | Q1 2024: $260.4 thousand | Q2 2024: $239.8 thousand | Q3 2024: $369.6 thousand | Q1 2025: $236.1 thousand | Q2 2025: $325.6 thousand | Q3 2025: $377.8 thousand.
- Over the full 13 years of available data (2013 to 2025), Inhibitor Therapeutics, Inc.'s Research And Development Expense has grown by 59.3%.
- Historical annual values: Fiscal year 2025: $1.70 million | Fiscal year 2024: $1.76 million | Fiscal year 2023: $1.38 million | Fiscal year 2022: $6.2 thousand | Fiscal year 2021: $4.9 thousand | Fiscal year 2020: $185.3 thousand | Fiscal year 2019: $1.21 million | Fiscal year 2018: $2.63 million | Fiscal year 2017: $2.23 million | Fiscal year 2016: $2.64 million | Fiscal year 2015: $1.68 million | Fiscal year 2014: $2.43 million | Fiscal year 2013: $1.07 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: